PMID- 27810089
OWN - NLM
STAT- MEDLINE
DCOM- 20170524
LR  - 20231112
IS  - 1476-5616 (Electronic)
IS  - 0033-3506 (Print)
IS  - 0033-3506 (Linking)
VI  - 142
DP  - 2017 Jan
TI  - Risk of hospitalization and death following prostate biopsy in Scotland.
PG  - 102-110
LID - S0033-3506(16)30303-1 [pii]
LID - 10.1016/j.puhe.2016.10.006 [doi]
AB  - OBJECTIVE: To investigate the risk of hospitalization and death following 
      prostate biopsy. STUDY DESIGN: Retrospective cohort study. METHODS: Our study 
      population comprised 10,285 patients with a record of first ever prostate biopsy 
      between 2009 and 2013 on computerized acute hospital discharge or outpatient 
      records covering Scotland. Using the general population as a comparison group, 
      expected numbers of admissions/deaths were derived by applying age-, sex-, 
      deprivation category-, and calendar year-specific rates of hospital 
      admissions/deaths to the study population. Indirectly standardized hospital 
      admission ratios (SHRs) and mortality ratios (SMRs) were calculated by dividing 
      the observed numbers of admissions/deaths by expected numbers. RESULTS: Compared 
      with background rates, patients were more likely to be admitted to hospital 
      within 30 days (SHR 2.7; 95% confidence interval 2.4, 2.9) and 120 days (SHR 4.0; 
      3.8, 4.1) of biopsy. Patients with prior co-morbidity had higher SHRs. The risk 
      of death within 30 days of biopsy was not increased significantly (SMR 1.6; 0.9, 
      2.7), but within 120 days, the risk of death was significantly higher than 
      expected (SMR 1.9; 1.5, 2.4). The risk of death increased with age and tended to 
      be higher among patients with prior co-morbidity. Overall risks of 
      hospitalization and of death up to 120 days were increased both in men diagnosed 
      and those not diagnosed with prostate cancer. CONCLUSIONS: Higher rates of 
      adverse events in older patients and patients with prior co-morbidity emphasizes 
      the need for careful patient selection for prostate biopsy and justifies ongoing 
      efforts to minimize the risk of complications.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Brewster, D H
AU  - Brewster DH
AD  - NHS National Services Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, 
      Scotland, UK; Centre for Population Health Sciences, University of Edinburgh, 
      Edinburgh, Scotland, UK. Electronic address: David.Brewster@nhs.net.
FAU - Fischbacher, C M
AU  - Fischbacher CM
AD  - NHS National Services Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, 
      Scotland, UK; Centre for Population Health Sciences, University of Edinburgh, 
      Edinburgh, Scotland, UK.
FAU - Nolan, J
AU  - Nolan J
AD  - NHS National Services Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, 
      Scotland, UK.
FAU - Nowell, S
AU  - Nowell S
AD  - NHS National Services Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, 
      Scotland, UK.
FAU - Redpath, D
AU  - Redpath D
AD  - NHS National Services Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, 
      Scotland, UK.
FAU - Nabi, G
AU  - Nabi G
AD  - Section of Academic Urology, Cancer Research Division, School of Medicine, 
      Ninewells Hospital, Dundee, Scotland, UK; Department of Surgical Urology, 
      Ninewells Hospital, NHS Tayside, Dundee, Scotland, UK.
LA  - eng
GR  - CZH/4/1039/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
DEP - 20161031
PL  - Netherlands
TA  - Public Health
JT  - Public health
JID - 0376507
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy/*adverse effects
MH  - *Death
MH  - Hospitalization/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostate/*pathology
MH  - Retrospective Studies
MH  - Risk
MH  - Scotland/epidemiology
PMC - PMC5226055
OTO - NOTNLM
OT  - Biopsy
OT  - Complications
OT  - Hospitalization
OT  - Morbidity
OT  - Mortality
OT  - Prostate
EDAT- 2016/11/05 06:00
MHDA- 2017/05/26 06:00
PMCR- 2017/01/01
CRDT- 2016/11/05 06:00
PHST- 2016/05/16 00:00 [received]
PHST- 2016/09/22 00:00 [revised]
PHST- 2016/10/04 00:00 [accepted]
PHST- 2016/11/05 06:00 [pubmed]
PHST- 2017/05/26 06:00 [medline]
PHST- 2016/11/05 06:00 [entrez]
PHST- 2017/01/01 00:00 [pmc-release]
AID - S0033-3506(16)30303-1 [pii]
AID - 10.1016/j.puhe.2016.10.006 [doi]
PST - ppublish
SO  - Public Health. 2017 Jan;142:102-110. doi: 10.1016/j.puhe.2016.10.006. Epub 2016 
      Oct 31.